AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02490735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced Killer Cells
Description: chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
Study NCT02537977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-directed CAR-T cells
Description: CD19-directed CAR-T cell infusion will be given by vein
Study NCT00248625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
Study NCT00248625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
Study NCT00698854 — intervention group
Intervention type: DEVICE
Intervention: Vanguard™ Complete Knee System
Description: Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
Study NCT00698854 — intervention group
Intervention type: DEVICE
Intervention: Vanguard™ Patient-Specific Femur
Description: Primary Total Knee System used with Signature technique to provide a patient-specific femur
Study NCT00148278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine and dobutamine
Description: continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
Study NCT00148278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine plus placebo of dobutamine
Description: epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
Study NCT02428361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologically active human fecal material, OpenBiome
Description: Fecal microbiota transplant
Study NCT04522895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Participants receive up to 12 cycles of Enasidenib.
Study NCT00435409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib + Capecitabine
Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m\^2 per day \[1000 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons.
Study NCT00435409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine administered orally at a starting dose of 2500 mg/m\^2 per day \[1250 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
Study NCT04436991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: At predefined time points through a venous catheter already in place. Max. volume to be withdrawn: Maximum 4ml/sample. Maximum 10 samples/patient.~A last blood sample will be taken, if necessary, after the end of antibiotic therapy, between day 7 and day 14. Though blood results preferably will be used from available data from tests already done during standard treatment.~Samples are collected in lithium-heparin tubes (without gel) and centrifuged immediately (within a maximum of 30 minutes after sampling) at room temperature: 8 minutes at 1885g.~Plasma is then collected and divided in two separated labelled Eppendorf tubes 1.5 ml and immediately frozen at - 80 °C. If this is not immediately possible, tubes are frozen at - 20 °C and at regular time points transferred to a freezer at - 80 °C (minimum twice a day).
Study NCT04436991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum sample
Description: Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
Study NCT04436991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hemoculture
Description: Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
Study NCT04436991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample
Description: Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
Study NCT04474470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT219
Description: Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors
Study NCT04474470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT219 and ERBITUX® - Dose Escalation
Description: Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma
Study NCT04474470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT219 and ERBITUX® - Expansion
Description: Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Study NCT04687475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Tool (Mobile Spirometry and Survey)
Description: The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISS©), with permission from the Seattle Quality of Life Group.
Study NCT02381561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02381561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02381561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02381561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropidoxuridine
Description: Given PO
Study NCT03564600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aging Back Clinics management
Description: Personalized care is delivered that is guided by published algorithms for each component condition identified by a trained provider.
Study NCT01231984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 mm x 32G Pen Needle
Description: During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
Study NCT01231984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8mm x 31G Pen Needle
Description: During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
Study NCT01231984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12.7mm x 29G Pen Needle
Description: During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
Study NCT03541850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
Study NCT03541850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03541850 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT02325596 — intervention group
Intervention type: GENETIC
Intervention: miRNA mimics or inhibitors
Description: DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
Study NCT00642200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein hernioplasty
Study NCT00642200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TEP
Study NCT03316781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX03
Description: 80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
Study NCT03316781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
Study NCT01584869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Study NCT04780867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed vaccination
Description: First and second hepatitis B vaccinations will be delayed by 1 month in the interventional group to establish whether changes in psychosocial and lifestyle factors during training impact immune health.
Study NCT00759590 — intervention group
Intervention type: PROCEDURE
Intervention: CT scan and Pressure volume curve
Description: CT scan
Study NCT00907426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution
Description: Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
Study NCT00907426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.03% solution
Description: Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
Study NCT00907426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle solution
Description: Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
Study NCT04252911 — intervention group
Intervention type: OTHER
Intervention: Bispectral index score
Description: Bis value from two sites gives similar results
Study NCT02455245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Vincristine
Description: Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV
Study NCT02455245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Vincristine
Description: Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV
Study NCT02455245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV
Study NCT03028766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 is a potent, selective small molecule inhibitor of WEE1
Study NCT03028766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy drug
Study NCT03028766 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Intensity Modulated Radiotherapy
Study NCT02218372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin oral suspension
Description: Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
Study NCT02218372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin tablets
Description: Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
Study NCT02218372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin oral liquid
Description: Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
Study NCT02218372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin capsules
Description: Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
Study NCT03957954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cLSC
Description: Transplantation of cLSC
Study NCT03957954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scleral contact lens (SCL)
Description: Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
Study NCT01481922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whitacre 24 gauge
Description: Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
Study NCT01481922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whitacre 22 gauge
Description: Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
Study NCT02182622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02182622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02182622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study NCT02340793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Counterweight Plus
Description: A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of >15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
Study NCT01598935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nutrition
Description: protein-based food
Study NCT01598935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition
Description: protein-based food
Study NCT01962935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4721
Description: Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
Study NCT01962935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4721
Description: Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
Study NCT01962935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A - multiple ascending dose daily
Study NCT01962935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5069
Description: Part B - one dose decided after part A, twice a day
Study NCT01184586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention - ESWT Storz Duolith high energy
Description: Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
Study NCT01184586 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]
Description: Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
Study NCT01612338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted
Description: Targeted letter and booklet
Study NCT01612338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Tailored
Description: Tailored letter and booklet, enhanced family communication and support brochure
Study NCT00436332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00436332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT04638907 — intervention group
Intervention type: PROCEDURE
Intervention: Assessment of NM block
Description: Observation of resulting course of NM block under teratment and monitoring as described.
Study NCT05360069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear stapler
Description: Linear stapler is adopted in esophagojejunostomy
Study NCT05360069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circular stapler
Description: Circular stapler is adopted in esophagojejunostomy
Study NCT00062439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: During induction:50 mg/m2,IV on Days 1, 8, 29 \& 36. In any appropriate vehicle over 60 minutes
Study NCT00062439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
Study NCT00062439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
Study NCT00062439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
Study NCT00062439 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
Study NCT00476125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary manipulation ketogenic diet
Description: Subjects will consume a ketogenic diet for 3 days.
Study NCT00476125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Manipulation - 12 day ketogenic diet
Description: Subjects will consume a ketogenic diet for 12 days.
Study NCT00476125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16 Hour Fast
Description: Subjects will fast for 16 hours.
Study NCT03212911 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
Study NCT04308421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red light
Description: Low irradiation 650 nm +/- 5 nm red light
Study NCT02352025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
Study NCT04291651 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.
Study NCT04024150 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
Study NCT01527149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous HDC-ASCT
Study NCT01527149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01527149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV